Digoxin bioavailability during quinidine administration

W. David Hager, Michael Mayersohn, Penelope E. Graves

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Digoxin serum concentration rises in the presence of quinidine. To determine whether quinidine alters digoxin bioavailability, six subjects received 1.0 rag of digoxin intravenously alone and by mouth on alternate weeks during steady-state oral quinidine administration. The area under the digoxin concentration: tune curves (AUC) and the amount of digoxin excreted in the urine (Xuχ) were determined for the 96 hr after each of the four experiments. Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (±S.D.) 73.5 ± 8.6% and 79.5 ± 22.6% (P > 0.05),for serum and 69.8 ± 6.8% and 70.2 ± 10.5% (P > 0.05), for urine. There was no difference in the steady-state quinidine serum concentration during the 4 clays after intravenous and oral digoxin. We conclude that quinidine does not alter digoxin bioavailability and therefore that altered absorption does not explain the rise in digoxin serum concentration in the presence of quinidine.

Original languageEnglish (US)
Pages (from-to)594-599
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume30
Issue number5
StatePublished - Nov 1981

Fingerprint

Quinidine
Digoxin
Biological Availability
Serum
Urine
Area Under Curve
Oral Administration
Mouth

ASJC Scopus subject areas

  • Pharmacology

Cite this

Digoxin bioavailability during quinidine administration. / David Hager, W.; Mayersohn, Michael; Graves, Penelope E.

In: Clinical Pharmacology and Therapeutics, Vol. 30, No. 5, 11.1981, p. 594-599.

Research output: Contribution to journalArticle

David Hager, W. ; Mayersohn, Michael ; Graves, Penelope E. / Digoxin bioavailability during quinidine administration. In: Clinical Pharmacology and Therapeutics. 1981 ; Vol. 30, No. 5. pp. 594-599.
@article{cff52785688344168057637e18d4766a,
title = "Digoxin bioavailability during quinidine administration",
abstract = "Digoxin serum concentration rises in the presence of quinidine. To determine whether quinidine alters digoxin bioavailability, six subjects received 1.0 rag of digoxin intravenously alone and by mouth on alternate weeks during steady-state oral quinidine administration. The area under the digoxin concentration: tune curves (AUC) and the amount of digoxin excreted in the urine (Xuχ) were determined for the 96 hr after each of the four experiments. Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (±S.D.) 73.5 ± 8.6{\%} and 79.5 ± 22.6{\%} (P > 0.05),for serum and 69.8 ± 6.8{\%} and 70.2 ± 10.5{\%} (P > 0.05), for urine. There was no difference in the steady-state quinidine serum concentration during the 4 clays after intravenous and oral digoxin. We conclude that quinidine does not alter digoxin bioavailability and therefore that altered absorption does not explain the rise in digoxin serum concentration in the presence of quinidine.",
author = "{David Hager}, W. and Michael Mayersohn and Graves, {Penelope E.}",
year = "1981",
month = "11",
language = "English (US)",
volume = "30",
pages = "594--599",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Digoxin bioavailability during quinidine administration

AU - David Hager, W.

AU - Mayersohn, Michael

AU - Graves, Penelope E.

PY - 1981/11

Y1 - 1981/11

N2 - Digoxin serum concentration rises in the presence of quinidine. To determine whether quinidine alters digoxin bioavailability, six subjects received 1.0 rag of digoxin intravenously alone and by mouth on alternate weeks during steady-state oral quinidine administration. The area under the digoxin concentration: tune curves (AUC) and the amount of digoxin excreted in the urine (Xuχ) were determined for the 96 hr after each of the four experiments. Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (±S.D.) 73.5 ± 8.6% and 79.5 ± 22.6% (P > 0.05),for serum and 69.8 ± 6.8% and 70.2 ± 10.5% (P > 0.05), for urine. There was no difference in the steady-state quinidine serum concentration during the 4 clays after intravenous and oral digoxin. We conclude that quinidine does not alter digoxin bioavailability and therefore that altered absorption does not explain the rise in digoxin serum concentration in the presence of quinidine.

AB - Digoxin serum concentration rises in the presence of quinidine. To determine whether quinidine alters digoxin bioavailability, six subjects received 1.0 rag of digoxin intravenously alone and by mouth on alternate weeks during steady-state oral quinidine administration. The area under the digoxin concentration: tune curves (AUC) and the amount of digoxin excreted in the urine (Xuχ) were determined for the 96 hr after each of the four experiments. Values for digoxin bioavailability relative to the corresponding intravenous study in the absence and presence of quinidine were (±S.D.) 73.5 ± 8.6% and 79.5 ± 22.6% (P > 0.05),for serum and 69.8 ± 6.8% and 70.2 ± 10.5% (P > 0.05), for urine. There was no difference in the steady-state quinidine serum concentration during the 4 clays after intravenous and oral digoxin. We conclude that quinidine does not alter digoxin bioavailability and therefore that altered absorption does not explain the rise in digoxin serum concentration in the presence of quinidine.

UR - http://www.scopus.com/inward/record.url?scp=0019644278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019644278&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 594

EP - 599

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -